DBV Technologies Announces Participation in March Investor Conferences

DBV Technologies, a late-stage biopharmaceutical firm, will engage in key investor conferences this March. The company plans to present at the Citizens Life Sciences Conference on March 10 and hold one-on-one meetings at the Leerink Partners Global Healthcare Conference on March 11.

The Citizens event features a fireside chat scheduled for 1:40 pm ET, allowing stakeholders to gain insights directly from DBV's representatives. The session will be available via live webcast, with recordings accessible on the company's website for 90 days post-event.

DBV Technologies focuses on addressing food allergies through its VIASKIN® patch technology, designed to reform the immune response to allergens. This technology is primarily aimed at treating peanut allergies in young children.